| value |
{"aggregator_url":"https://www.nasdaq. {"aggregator_url":"https://www.nasdaq.com/articles/insider-sells-200k-shares-biotech-company-nuvation-bio-nuvb","as_of":"2026-04-13T05:56:02.155210+00:00","canonical_url":"https://www.fool.com/coverage/filings/2026/04/13/insider-sells-200k-shares-of-biotech-company-nuvation-bio-nuvb/","enrichment":{"aggregator_url":"https://www.nasdaq.com/articles/insider-sells-200k-shares-biotech-company-nuvation-bio-nuvb","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_c10d4ed434d94f96","canonical_host":"fool.com","canonical_is_aggregator":false,"canonical_url":"https://www.fool.com/coverage/filings/2026/04/13/insider-sells-200k-shares-of-biotech-company-nuvation-bio-nuvb/","content_type":"text/html; charset=utf-8","enriched_at":"2026-04-13T11:33:59.726751+00:00","extraction_method":"trafilatura","fetched_description":"Key Points200,000 Class A shares were sold for a transaction value of `$904,000 at around $4.52 per share on April 6, 2026.","fetched_title":"Insider Sells 200K Shares of Biotech Company Nuvation Bio (NUVB) | Nasdaq","final_url":"https://www.nasdaq.com/articles/insider-sells-200k-shares-biotech-company-nuvation-bio-nuvb","html_truncated":false,"paywall_likely":false,"publisher_domain":"fool.com","publisher_resolution":"canonical_url","requested_url":"https://www.nasdaq.com/articles/insider-sells-200k-shares-biotech-company-nuvation-bio-nuvb","source_event_id":"evt_277fba3bfc3a","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"fp":"97c085205a24e186","kind":"unusual_volume","published_at":"2026-04-13T04:24:41+00:00","publisher_domain":"fool.com","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["April 6, 2026"],"entities":[{"asset_class":"equity","name":"Nuvation Bio","relevance":"high","symbol":"NUVB","type":"company"},{"asset_class":"person","name":"Kerry Wentworth","relevance":"high","symbol":"","type":"insider"},{"asset_class":"person","name":"Wentworth","relevance":"high","symbol":"","type":"insider_holder"}],"event_type":"other","information_gaps":["The signal type is 'discovery_unusual_volume_delta', but the provided text does not include any volume ratio vs average or baseline volume figures.","The article does not provide a specific catalyst tied to unusual trading volume; it frames the sale as option exercise/compensation-related.","No confirmation or denial of any market-moving news around the sale is provided in the text excerpt.","catalyst_hypothesis_most_likely_if_any_from_text:option_exercise_and_compensation_locking_in_profits","information_gaps_additional_context_missing_if_any: whether there was any concurrent news or broader market reaction is not stated."],"key_facts":["200,000 Class A shares were sold for a total transaction value of approximately $904,000.","The weighted average purchase price cited is about $4.52 per share (based on SEC Form 4).","The sale occurred on April 6, 2026.","The sale accounted for 79.0% of Wentworth's direct Class A holdings.","Wentworth's direct Class A holdings decreased from 253,000 shares to 53,000 shares.","The transaction followed exercise of options with immediate sale.","No indirect entities (e.g., family trusts) were involved in the transaction.","Wentworth retained stock options (Right to Buy) for 700,000 shares that can be converted to Class A common stock.","The article states this was the first open-market sale in the recent period (as described in the text)."],"numeric_claims":[{"label":"shares_sold","value":"200,000"},{"label":"transaction_value_usd","value":"~904,000"},{"label":"price_per_share_usd","value":"~4.52"},{"label":"percent_of_direct_holdings_sold","value":"79.0% (79.05% stated)"}],"primary_claim":"On April 6, 2026, Nuvation Bio CRO Kerry Wentworth sold 200,000 Class A shares for approximately $904,000 (~$4.52/share), reducing his direct Class A holdings from 253,000 to 53,000 shares (about 79%).","relevance_score":0.62,"sentiment":"neutral","source_quality":"high","summary":"Nuvation Bio (NUVB) insider Kerry Wentworth (CRO) sold 200,000 Class A shares on April 6, 2026 for about $904,000 (~$4.52/share) after exercising options. The sale represented ~79% of his direct Class A holdings, while he retained 700,000 stock options that could convert to shares.","topics":["insider trading","SEC Form 4","stock options","biotech","Nuvation Bio","executive compensation"]},"source":"Nasdaq Markets","source_domain":"fool.com","summary":"Key Points200,000 Class A shares were sold for a transaction value of `$904,000 at around $4.52 per share on April 6, 2026.","tickers":["NUVB"],"title":"Insider Sells 200K Shares of Biotech Company Nuvation Bio (NUVB)","url":"https://www.fool.com/coverage/filings/2026/04/13/insider-sells-200k-shares-of-biotech-company-nuvation-bio-nuvb/"}... |